By addressing these gaps, we can ensure that the benefits of HER2-targeted therapies reach all patients, ultimately improving survival outcomes and promoting greater health equity in the management of metastatic HR−/HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.